SS
JANX icon

SBI Securities’s Janux Therapeutics JANX Stock Holding History

SBI Securities’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15 Hold
1
– – ﹤0.01% 3888
2026
Q1 		$14 Sell
1
-40
-98% -$548 ﹤0.01% 3808
2025
Q4 		$566 Buy
+41
New +$964 ﹤0.01% 2824
2025
Q2 		– Sell
-3
Closed -$81 – 4188
2025
Q1 		$81 Hold
3
– – ﹤0.01% 3514
2024
Q4 		$161 Buy
+3
New +$159 ﹤0.01% 3319

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

SBI Securities's JANX Position: Q2 2026 in Review

SBI Securities held its Janux Therapeutics (JANX) position steady in Q2 2026 at 1 share worth $15. The position accounts for ﹤0.01% of the portfolio, ranked #3888.

SBI Securities first reported a position in JANX in Q4 2024 and has held it in 5 quarters since. The position peaked at $566 in Q4 2025. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • SBI Securities held 1 share of Janux Therapeutics worth $15 as of Q2 2026.
  • SBI Securities left its Janux Therapeutics share count unchanged in Q2 2026.
  • Janux Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3888 holding.
  • SBI Securities first reported a position in Janux Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • SBI Securities's Janux Therapeutics position peaked at $566 in Q4 2025.
  • 198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.